J&J Darzalex Faspro Use In Smoldering Myeloma Supported By ODAC Despite Reservations About Over-Treatment; Will FDA And Sponsor Agree On “High Risk” Claim?

FDA Offers More Support For States Who Want To Import Drugs From Cananda; “Pre-SIP” Meetings, Feedback In Fall Among Plans

Prevision Policy Clips | Trump Administration “In Negotiation” With Drug Companies Over MFN

FDA’s Two-Tier COVID “Framework” Unveiled: RCTs Required To Support Boosters In Young, Healthy Individuals, But Policy Does Not Extend To Other Vaccines

Columvi STARGLO Supplement Shot Down By ODAC; FDA Will Be Pressing Sponsors To Choose Optimal Control Arms For US Patients In Global Trials

MFN 2.0: HHS Sets Pricing Target To Lowest Price In An OECD Country; Trump Administration Wants Manufacturer Commitments “In Coming Weeks”

COVID Booster Meeting: FDA Releases Bare Bones Briefing Document Ahead Of May 22 VRBPAC; New “Framework” Mandates Randomized Trials In Future

The Makary Moment? FDA Commissioner, CBER’s Prasad Make Brief Appearance At ODAC Review Of Genentech’s Columvi

Prevision Policy Clips | FDA COVID Vaccine Framework Will Be Unveiled At 1 PM

Urogen UGN-102 ODAC Review Stems From FDA’s Preference For Randomized Trial In Low-Grade Bladder Cancer; Novel Mitomycin Formulation Role Versus TURBT Is Key Topic

FDA AI Policy In Flux: Draft Guidance Should Not Be Viewed As Reflecting Current Agency Views, Former HELP Staffer Advises

FDA Commissioner Makary’s PR Push Starts With Public Roundtable Series: HRT, Talc Are Initial Topics; Vaccine “Framework” Coming From CBER’s Prasad

PDUFA VIII Predictions: AI, Domestic Manufacturing Policies May Be Focus; Anti-Regulatory (And Anti-Industry) Administration May Make For Smaller Program

Prevision Policy Clips | FDA Commissioner Makary’s First Appropriations Hearing Set For May 22

Pfizer Faces Skeptical FDA For Talzenna “All Comers” Prostate Cancer Indication, But Can ODAC Say No To Survival Benefit?

Janssen Darzalex Faspro For Smoldering Myeloma: PFS Benefit In “Precursor” Condition Doubted By FDA Ahead Of ODAC; New CBER Director Prasad Is Also A Skeptic

Genentech Columvi Confirmatory Trial Questioned By FDA; ODAC Will Be Asked If Positive Results Apply To US Population Given Impact Of China/Asia Patients On Efficacy Outcomes

Prevision Policy Clips | GDUFA IV Reauthorization Kick-Off Meeting Set For July 11, FDA Formally Announces July 14 PDUFA VIII Public Meeting

Prevision Policy Clips | Biohaven Troriluzole For SCA Will Go Before An FDA Advisory Committee

RFK Embraces Streamlined Development Path For New Drugs During Budget Hearings; Says Industry 340B Concerns Need Attention, But Pledges To Protect Rural Providers

CMMI Will Look To More Drug Demos In Future Years, Sickle Cell Gene Therapy Model May Be Blueprint For Drugs That Get At “Root Causes” Of Conditions

Prevision Policy Clips | Finance Committee PBM Legislation Will Advance Following Reconciliation Process, Sen. Grassley (R-Iowa) Says

CMS Outlines Medicare Drug Price Re-Negotiation Process; Few Of First 25 Products Likely To Be Eligible – But Xarelto And Tradjenta May Be

Medicare Price Negotiation Year 3: CMS Proposes Tweaks But No Major Revisions, Suggests Biologic SubQ Combos May Not Be Separate From Original Brand

CBER Touts Cell/Gene Therapy “Platform Technology,” CMC Pilot To Speed Development; Others Float Public Cost Recovery Model For Rare Diseases